1. The First Clinical Medical College, Mudanjiang Medical University；
2. Department of Cardiology, Hongqi Hospital Affiliated to Mudanjiang Medical University
Abstract：The drug treatment of chronic heart failure has changed from strengthening heart, diuresis and vasodilation
to inhibiting neuroendocrine. As a new generation of neuroendocrine inhibitor, Sacubitril Valsartan has been paid more
and more attention in recent years. It has been found that its efficacy is not only limited to patients with heart failure
with reduced ejection fraction (HFrEF), but also benefit patients with non-HFrEF. In addition, existing studies have
shown that Sacubitril Valsartan shows superiority in heart failure complicated with other diseases. This paper reviews
the efficacy of Sacubitril Valsartan in the treatment of non-HFrEF and heart failure complicated with other diseases,and looks forward to the application of Sacubitril Valsartan in a wider population.
Ponikowski P, Voors AA,Anker SD, et al.2016 ESC Guide-lines for the diagnosis and treatment of acute and chronicheart failure:The Task Force for the diagnosis and treat-ment of acute and chronic heart failure of the European So-ciety of Cardiology (ESC) Developed with the special con-tribution of the Heart Failure Association( HFA ) of theESC[J].Eur Heart J,2016,37(27):2129-2200.
Moliner P, Lupon J ,Barallat J,et al.Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejec-tion fraction[J].Int J Cardiol, 2018,257:188-192.
[10]
Solomon SD , Vaduganathan M ,L Claggett B,et al.Sacubi-tril/Valsartan Across the Spectrum of Ejection Fraction inHeart Failure[JJ.Circulation,2020,141(5):352-361.
[11]
Vaduganathan M ,Jhund PS, Claggett BL,et al.A putative placebo analysis of the effects of sacubitril/valsartan inheart failure across the full range of ejection fraction[J].Eur Heart J,2020,41(25):2356-2362.
Wehland M,Simonsen U , Buus NH ,et al.An evaluation of the fixed -dose combination sacubitril/valsartan for thetreatment of arterial hypertension[J].Expert Opin Pharma-cother , 2020,21(10):1133-1143.
[14]
Wang 'TD,Tan RS,Lee HY ,et al.Effects of Sacubitril/Val-sartan (LCZ696) on Natriuresis , Diuresis , Blood Pres-sures ,and NT一proBNP in Salt -Sensitive Hypertension[J].Hypertension, 2017,69(1):32-41.
[15]
Supasyndh O, Wang J , Hafeez K,et al.Efficacy and Safety of Sacubitril/Valsartan(LCZ696)Compared With Olme-sartan in Elderly Asian Patients (>/=65 Years)With Sys-tolic Hypertension[J].Am J Hypertens,2017,30( 12):1163-1169.
[ 16]
Jackson AM ,Jhund PS,Anand IS,et al.Sacubitril-valsartan as a treatment for apparent resistant hypertension in patientswith heart failure and preserved ejection fraction[J].EurHeart J,2021,42(36):3741-3752.
[21]
Campbell DJ.Long-term neprilysin inhibition-implications for ARNIs[J]J.Nat Rev Cardiol, 2017,14(3):171-186.
[22]
Coue M ,Moro C.Natriuretic peptide control of energy bal-ance and glucose homeostasis[J].Biochimie, 2016,124:84-91.
Geng Q, Yan R, Wang Z,et al.Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hyperten-sion : A Meta-Analysis of Randomized Controlled 'Trials[J].Cardiology , 2020,145(9):589-598.
[18]
Unger T, Borghi C,Charchar F,et al.2020 Intermational Society of Hypertension global hypertension practice guide-lines[J].J Hypertens,2020,38(6):982-1004.
[19]
Ali A,Bain S,Hicks D ,et al.SGLT2 Inhibitors : Cardiovas-cular Benefits Beyond HbA1c -Translating Evidence intoPractice[J].Diabetes Ther ,2019,10(5):1595-1622.
[20]
Vemes E,Ducharme A , Bourassa MG,et al.Enalapril re-duces the incidence of diabetes in patients with chronicheart failure : insight from the Studies Of Left VentricularDysfunction (SOLVD)[J].Circulation ,2003,107(9):1291-1296.
[23]
Seferovic JP , Claggett B, Seidelmann SB,et al.Effect of sacubitril/valsartan versus enalapril on glycaemic controlin patients with heart failure and diabetes : a post -hocanalysis from the PARADIGM-HF trial[J].Lancet DiabetesEndocrinol , 2017,5(5):333-340.
[24]
Jordan J ,Stinkens R,Jax T,et al.Improved Insulin Sensi-tivity With Angiotensin Receptor Neprilysin Inhibition inIndividuals With Obesity and Hypertension[J].Clin Pharma-col Ther,2017,101(2):254-263.
[25]
Feldman EL,Nave KA ,Jensen 'TS,et al.New Horizons in Di-abetic Neuropathy : Mechanisms,Bioenergetics, and Pain[J].Neuron,2017,93(6): 1296-1313.
[27]
Testani JM , Kimmel SE, Dries DL,et al.Prognostic impor-tance of early worsening renal function after initiation ofangiotensin -converting enzyme inhibitor therapy in pa-tients with cardiac dysfunction[J].Circ Heart Fail , 2011 ,4(6):685-691.
[28]
Kim HJ,Lee MH ,Jo SH,et al.Effects of Angiotensin-Con-verting Enzyme Inhibitorsand Angiotensin -ReceptorBlockers in Heart Failure With Chronic Kidney Disease-Propensity Score Matching Analysis[J].Circ J ,2019,84( 1):83-90.
[29]
Packer M, Califf RM , Konstam MA, et al.Comparison ofomapatrilat and enalapril in patients with chronic heartfailure : the Omapatrilat Versus Enalapril Randomized Trialof Utility in Reducing Events(OVERTURE)[J.Circula-tion . 2002.106(8).920-926.
[30]
Haynes R, Judge PK,Staplin N,et al.Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With ChronicKidney Disease[J].Circulation,2018,138( 15) :1505-1514.
[31]
Pontremoli R,Borghi C,Perrone Filardi P.Renal protection in chronic heart failure:focus on sacubitril/valsartan[J].EurHeart J Cardiovasc Pharmacother , 2021,7(5):445-452.
京公网安备 11010502046607号